Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTACT-2: Intercalated Erlotinib + Chemo in Advanced NSCLC
NCT00883779Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2009
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Erlotinib Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival up to 1.5 years. Started Apr 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00883779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883779.